Detection of preclinical Parkinson disease in at-risk family members with use of [123I]β-CIT and SPECT: An exploratory study

D. M. Maraganore, M. K. O'Connor, James Howard Bower, K. M. Kuntz, S. K. McDonnell, Daniel J Schaid, Walter A Rocca

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Objective: To explore whether the radioligand 2β-carboxymethoxy-3β- (4-[123I] iodophenyl) tropane ([123I]β-CIT) and single-photon emission computed tomography (SPECT) can detect decreased striatal uptake in at-risk relatives of patients with Parkinson disease (PD). Patients and Methods: Ten PD patients, 10 at-risk first-degree relatives of PD patients, and 10 controls underwent [123I]β-CIT and SPECT brain imaging. Their striatal uptake ratios were compared. Results: Age-adjusted specific to nonspecific striatal uptake ratios were lower in patients compared with controls and with relatives; however, ratios were similar in relatives and controls. Among relatives, ratios were consistently lower in subgroups postulated to be at higher risk for preclinical PD. Conclusion: Our findings provide preliminary support that [123I]β-CIT and SPECT may detect decreased striatal uptake in relatives of PD patients postulated to be at higher risk for PD.

Original languageEnglish (US)
Pages (from-to)681-685
Number of pages5
JournalMayo Clinic Proceedings
Volume74
Issue number7
StatePublished - 1999

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this